Novavax Global Commercial Operations and COVID-19 Vaccine Update

Development of COVID-19-Influenza Combination (CIC) vaccine is driven by expectations of future market dynamics COVID-19 • • • • novavax Anticipated need for annual seasonal vaccination Emergence of variants Influenza • Waning immunity • Ongoing SARS-CoV-2 circulation Priority #3 Ongoing need for annual seasonal vaccination Opportunity for differentiation in older adults Adoption in high-income countries COVID-19-Influenza Combination (CIC) Vaccine Competitively positioned to support annual vaccination need Phase 2 trial initiated in December 2022 with -1,500 participants enrolled Data to inform Phase 3 trials for stand-alone influenza and CIC vaccine candidates 。 Topline results expected mid-year 2023 © 2023 NOVAVAX. All rights reserved. 18

View entire presentation